GSK (NYSE:GSK) Stock Rating Reaffirmed as Buy by Berenberg Bank

GSK (NYSE:GSK)‘s stock had its “buy” rating restated by equities research analysts at Berenberg Bank in a report released on Tuesday.

A number of other research firms have also recently weighed in on GSK. Weiss Ratings cut GSK from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Wolfe Research started coverage on shares of GSK in a research report on Friday. They issued an “outperform” rating and a $70.00 price objective for the company. Citigroup started coverage on GSK in a research report on Friday, July 24th. They set a “neutral” rating on the stock. Finally, Jefferies Financial Group upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $55.33.

GSK Trading Down 0.1%

Shares of GSK stock traded down $0.04 during mid-day trading on Tuesday, reaching $46.49. The company’s stock had a trading volume of 8,542,712 shares, compared to its average volume of 4,225,426. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $94.05 billion, a PE ratio of 14.54, a price-to-earnings-growth ratio of 2.09 and a beta of 0.33. The company’s 50 day simple moving average is $50.02 and its 200-day simple moving average is $51.83. GSK has a 12-month low of $42.85 and a 12-month high of $61.69.

GSK (NYSE:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. During the same period in the prior year, the firm earned $0.47 EPS. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts predict that GSK will post 4.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Sound Income Strategies LLC boosted its holdings in GSK by 2.7% in the third quarter. Sound Income Strategies LLC now owns 348,273 shares of the pharmaceutical company’s stock worth $16,209,000 after purchasing an additional 9,218 shares during the period. Wedmont Private Capital lifted its position in shares of GSK by 8.8% in the 3rd quarter. Wedmont Private Capital now owns 4,325 shares of the pharmaceutical company’s stock worth $201,000 after buying an additional 348 shares during the last quarter. Keystone Financial Planning Inc. boosted its holdings in shares of GSK by 8.0% in the 3rd quarter. Keystone Financial Planning Inc. now owns 211,232 shares of the pharmaceutical company’s stock valued at $10,175,000 after buying an additional 15,642 shares during the period. GAMMA Investing LLC grew its position in shares of GSK by 8.4% during the 3rd quarter. GAMMA Investing LLC now owns 12,286 shares of the pharmaceutical company’s stock valued at $592,000 after buying an additional 956 shares during the last quarter. Finally, Grove Bank & Trust raised its stake in GSK by 3.8% during the third quarter. Grove Bank & Trust now owns 5,859 shares of the pharmaceutical company’s stock worth $282,000 after acquiring an additional 215 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.